Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00522353 |
Recruitment Status :
Completed
First Posted : August 29, 2007
Last Update Posted : May 23, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity | Dietary Supplement: Oligofructose Dietary Supplement: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 48 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effect of Oligofructose Versus Placebo on Body Weight and Satiety Hormone Secretion in Overweight and Obese Adults. |
Study Start Date : | January 2007 |
Actual Primary Completion Date : | May 2007 |
Actual Study Completion Date : | August 2007 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Oligofructose
|
Dietary Supplement: Oligofructose
21 grams per day in distributed over 3 doses per day for 3 months
Other Name: Raftilose P95 |
Placebo Comparator: 2
Placebo
|
Dietary Supplement: Placebo
7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
Other Name: Maltrin M100 |
- Body weight [ Time Frame: 3 months ]
- Plasma satiety hormones [ Time Frame: 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- overweight or class I obese individuals with BMI between 25 kg/m2 and 34.9 kg/m2
- stable body weight in previous 3 months
Exclusion Criteria:
- Type 1 and Type 2 diabetes
- clinically significant cardiovascular abnormalities
- liver or pancreas disease
- major gastrointestinal surgeries
- are pregnant or lactating
- exhibit alcohol or drug dependence
- on drugs influencing appetite
- are following a diet or exercise regime designed for weight loss
- have a body mass greater than 350lb
- chronic use of antacids or bulk laxatives

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00522353
Canada, Alberta | |
Faculty of Kinesiology, Roger Jackson Centre for Health and Wellness Research | |
Calgary, Alberta, Canada, T2N 1N4 |
Principal Investigator: | Raylene A. Reimer, PhD, RD | University of Calgary |
Responsible Party: | Raylene Reimer, Associate Professor, University of Calgary |
ClinicalTrials.gov Identifier: | NCT00522353 |
Other Study ID Numbers: |
UC 20085 |
First Posted: | August 29, 2007 Key Record Dates |
Last Update Posted: | May 23, 2008 |
Last Verified: | May 2008 |
obesity weight loss satiety hormones body composition appetite ratings |
Overweight Body Weight |